JAMA:塞来昔布联合FOLFOX标准辅助化疗对结肠癌患者无病生存率的影响

2021-04-07 MedSci原创 MedSci原创

对于III期结肠癌患者中,在FOLFOX标准辅助化疗方案中加入塞来昔布对患者3年无病生存率无提高作用

尽管结直肠癌预防和治疗已获得了显著进步,但2021年美国预计结直肠癌死亡人数将达到52980 人,全球结直肠癌死亡人数将超过915880 人。临床统计发现,80%结肠直肠癌患者最初并没有出现转移,但约50%的区域淋巴结阳性(III期)患者会在前5年内复发。在观察性和随机研究中,环氧合酶2(COX-2)抑制剂与降低结直肠息肉和肿瘤风险有关。

近日研究人员考察了在氟尿嘧啶、亚叶酸钙和奥沙利铂(FOLFOX)辅助化疗方案基础上,添加塞来昔布对III期结肠癌患者无病生存率的影响。

本次III期临床研究在美国及加拿大开展,2526名III期结肠癌患者参与,随访至2020年8月10日,参与者每2周进行1次FOLFOX化疗,持续3或6个月,在3年内,随机接受塞来昔布(每日口服400毫克;n=1263)或安慰剂(n=1261)治疗。研究的主要终点为无病生存率,次要终点包括总生存率、不良事件和血管特异性事件。

参与者平均年龄61.0岁,1134名女性,2524名患者数据被纳入初步分析。治疗依从性方面,持续用药治疗2.75年以上或持续治疗直至疾病复发、死亡或不可接受的不良事件,塞来昔布组为70.8%,安慰剂组为69.9%。6年随访中,塞来昔布组共有337名患者出现疾病复发或死亡,而安慰剂组363名,塞来昔布组患者的3年无病生存率为76.3%,安慰剂组患者为73.4%(疾病复发或死亡的危险比[HR],0.89)。在指定辅助化疗持续时间内,塞来昔布治疗对无病生存率无显著影响。塞来昔布组5年总生存率为84.3%,安慰剂组为81.6%(死亡HR为0.86)。塞来昔布组14.6%的患者在接受FOLFOX治疗时出现高血压(任何级别),安慰剂组有10.9%.完成FOLFOX治疗后,塞来昔布组和安慰剂组肌酐水平升高2级或更高发生率分别为1.7%和0.5%。

组间无病生存率及总生存率差异

对于III期结肠癌患者中,在FOLFOX标准辅助化疗方案中加入塞来昔布对患者3年无病生存率无提高作用

原始出处

Jeffrey A. Meyerhardt et al. Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial .JAMA. April 6, 2021.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1256826, encodeId=b4e21256826a5, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Apr 09 11:03:31 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283836, encodeId=57bd1283836a6, content=<a href='/topic/show?id=082842228d3' target=_blank style='color:#2F92EE;'>#塞来昔布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42228, encryptionId=082842228d3, topicName=塞来昔布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Fri Apr 09 11:03:31 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455469, encodeId=8d521455469ef, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Fri Apr 09 11:03:31 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955329, encodeId=367995532910, content=明白了没有提高作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc12612169, createdName=yqbs11, createdTime=Thu Apr 08 22:57:44 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955118, encodeId=78bf955118d9, content=无提高作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210208/c3dc2580e0ac4c8191eae47c717138a5/1e85aea19cb54b3da3746e58584795cf.jpg, createdBy=a3975411105, createdName=Half, createdTime=Thu Apr 08 08:31:23 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036564, encodeId=aa7d1036564d2, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Apr 07 23:03:31 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955087, encodeId=e44395508e1b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210406/5c10cde452f54a839edb1f37a9ed13a6/44169360eb0a44cba38dd6d204ba7d2f.jpg, createdBy=11d95477523, createdName=回首向来萧瑟处, createdTime=Wed Apr 07 23:01:34 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955042, encodeId=f26f95504243, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210315/24d1758726dd4fabb0a861d94a0f4a61/12d8ebfef4a14a3ebeab5b4335ebb394.jpg, createdBy=b6ef5464690, createdName=谭术, createdTime=Wed Apr 07 21:04:52 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955037, encodeId=564495503efd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e815440258, createdName=ms6000001465244269, createdTime=Wed Apr 07 20:40:24 CST 2021, time=2021-04-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1256826, encodeId=b4e21256826a5, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Apr 09 11:03:31 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283836, encodeId=57bd1283836a6, content=<a href='/topic/show?id=082842228d3' target=_blank style='color:#2F92EE;'>#塞来昔布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42228, encryptionId=082842228d3, topicName=塞来昔布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Fri Apr 09 11:03:31 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455469, encodeId=8d521455469ef, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Fri Apr 09 11:03:31 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955329, encodeId=367995532910, content=明白了没有提高作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc12612169, createdName=yqbs11, createdTime=Thu Apr 08 22:57:44 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955118, encodeId=78bf955118d9, content=无提高作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210208/c3dc2580e0ac4c8191eae47c717138a5/1e85aea19cb54b3da3746e58584795cf.jpg, createdBy=a3975411105, createdName=Half, createdTime=Thu Apr 08 08:31:23 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036564, encodeId=aa7d1036564d2, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Apr 07 23:03:31 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955087, encodeId=e44395508e1b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210406/5c10cde452f54a839edb1f37a9ed13a6/44169360eb0a44cba38dd6d204ba7d2f.jpg, createdBy=11d95477523, createdName=回首向来萧瑟处, createdTime=Wed Apr 07 23:01:34 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955042, encodeId=f26f95504243, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210315/24d1758726dd4fabb0a861d94a0f4a61/12d8ebfef4a14a3ebeab5b4335ebb394.jpg, createdBy=b6ef5464690, createdName=谭术, createdTime=Wed Apr 07 21:04:52 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955037, encodeId=564495503efd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e815440258, createdName=ms6000001465244269, createdTime=Wed Apr 07 20:40:24 CST 2021, time=2021-04-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1256826, encodeId=b4e21256826a5, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Apr 09 11:03:31 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283836, encodeId=57bd1283836a6, content=<a href='/topic/show?id=082842228d3' target=_blank style='color:#2F92EE;'>#塞来昔布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42228, encryptionId=082842228d3, topicName=塞来昔布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Fri Apr 09 11:03:31 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455469, encodeId=8d521455469ef, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Fri Apr 09 11:03:31 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955329, encodeId=367995532910, content=明白了没有提高作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc12612169, createdName=yqbs11, createdTime=Thu Apr 08 22:57:44 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955118, encodeId=78bf955118d9, content=无提高作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210208/c3dc2580e0ac4c8191eae47c717138a5/1e85aea19cb54b3da3746e58584795cf.jpg, createdBy=a3975411105, createdName=Half, createdTime=Thu Apr 08 08:31:23 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036564, encodeId=aa7d1036564d2, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Apr 07 23:03:31 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955087, encodeId=e44395508e1b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210406/5c10cde452f54a839edb1f37a9ed13a6/44169360eb0a44cba38dd6d204ba7d2f.jpg, createdBy=11d95477523, createdName=回首向来萧瑟处, createdTime=Wed Apr 07 23:01:34 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955042, encodeId=f26f95504243, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210315/24d1758726dd4fabb0a861d94a0f4a61/12d8ebfef4a14a3ebeab5b4335ebb394.jpg, createdBy=b6ef5464690, createdName=谭术, createdTime=Wed Apr 07 21:04:52 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955037, encodeId=564495503efd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e815440258, createdName=ms6000001465244269, createdTime=Wed Apr 07 20:40:24 CST 2021, time=2021-04-07, status=1, ipAttribution=)]
    2021-04-09 linlin2314
  4. [GetPortalCommentsPageByObjectIdResponse(id=1256826, encodeId=b4e21256826a5, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Apr 09 11:03:31 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283836, encodeId=57bd1283836a6, content=<a href='/topic/show?id=082842228d3' target=_blank style='color:#2F92EE;'>#塞来昔布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42228, encryptionId=082842228d3, topicName=塞来昔布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Fri Apr 09 11:03:31 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455469, encodeId=8d521455469ef, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Fri Apr 09 11:03:31 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955329, encodeId=367995532910, content=明白了没有提高作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc12612169, createdName=yqbs11, createdTime=Thu Apr 08 22:57:44 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955118, encodeId=78bf955118d9, content=无提高作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210208/c3dc2580e0ac4c8191eae47c717138a5/1e85aea19cb54b3da3746e58584795cf.jpg, createdBy=a3975411105, createdName=Half, createdTime=Thu Apr 08 08:31:23 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036564, encodeId=aa7d1036564d2, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Apr 07 23:03:31 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955087, encodeId=e44395508e1b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210406/5c10cde452f54a839edb1f37a9ed13a6/44169360eb0a44cba38dd6d204ba7d2f.jpg, createdBy=11d95477523, createdName=回首向来萧瑟处, createdTime=Wed Apr 07 23:01:34 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955042, encodeId=f26f95504243, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210315/24d1758726dd4fabb0a861d94a0f4a61/12d8ebfef4a14a3ebeab5b4335ebb394.jpg, createdBy=b6ef5464690, createdName=谭术, createdTime=Wed Apr 07 21:04:52 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955037, encodeId=564495503efd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e815440258, createdName=ms6000001465244269, createdTime=Wed Apr 07 20:40:24 CST 2021, time=2021-04-07, status=1, ipAttribution=)]
    2021-04-08 yqbs11

    明白了没有提高作用

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1256826, encodeId=b4e21256826a5, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Apr 09 11:03:31 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283836, encodeId=57bd1283836a6, content=<a href='/topic/show?id=082842228d3' target=_blank style='color:#2F92EE;'>#塞来昔布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42228, encryptionId=082842228d3, topicName=塞来昔布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Fri Apr 09 11:03:31 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455469, encodeId=8d521455469ef, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Fri Apr 09 11:03:31 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955329, encodeId=367995532910, content=明白了没有提高作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc12612169, createdName=yqbs11, createdTime=Thu Apr 08 22:57:44 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955118, encodeId=78bf955118d9, content=无提高作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210208/c3dc2580e0ac4c8191eae47c717138a5/1e85aea19cb54b3da3746e58584795cf.jpg, createdBy=a3975411105, createdName=Half, createdTime=Thu Apr 08 08:31:23 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036564, encodeId=aa7d1036564d2, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Apr 07 23:03:31 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955087, encodeId=e44395508e1b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210406/5c10cde452f54a839edb1f37a9ed13a6/44169360eb0a44cba38dd6d204ba7d2f.jpg, createdBy=11d95477523, createdName=回首向来萧瑟处, createdTime=Wed Apr 07 23:01:34 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955042, encodeId=f26f95504243, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210315/24d1758726dd4fabb0a861d94a0f4a61/12d8ebfef4a14a3ebeab5b4335ebb394.jpg, createdBy=b6ef5464690, createdName=谭术, createdTime=Wed Apr 07 21:04:52 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955037, encodeId=564495503efd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e815440258, createdName=ms6000001465244269, createdTime=Wed Apr 07 20:40:24 CST 2021, time=2021-04-07, status=1, ipAttribution=)]
    2021-04-08 Half

    无提高作用

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1256826, encodeId=b4e21256826a5, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Apr 09 11:03:31 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283836, encodeId=57bd1283836a6, content=<a href='/topic/show?id=082842228d3' target=_blank style='color:#2F92EE;'>#塞来昔布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42228, encryptionId=082842228d3, topicName=塞来昔布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Fri Apr 09 11:03:31 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455469, encodeId=8d521455469ef, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Fri Apr 09 11:03:31 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955329, encodeId=367995532910, content=明白了没有提高作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc12612169, createdName=yqbs11, createdTime=Thu Apr 08 22:57:44 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955118, encodeId=78bf955118d9, content=无提高作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210208/c3dc2580e0ac4c8191eae47c717138a5/1e85aea19cb54b3da3746e58584795cf.jpg, createdBy=a3975411105, createdName=Half, createdTime=Thu Apr 08 08:31:23 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036564, encodeId=aa7d1036564d2, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Apr 07 23:03:31 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955087, encodeId=e44395508e1b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210406/5c10cde452f54a839edb1f37a9ed13a6/44169360eb0a44cba38dd6d204ba7d2f.jpg, createdBy=11d95477523, createdName=回首向来萧瑟处, createdTime=Wed Apr 07 23:01:34 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955042, encodeId=f26f95504243, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210315/24d1758726dd4fabb0a861d94a0f4a61/12d8ebfef4a14a3ebeab5b4335ebb394.jpg, createdBy=b6ef5464690, createdName=谭术, createdTime=Wed Apr 07 21:04:52 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955037, encodeId=564495503efd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e815440258, createdName=ms6000001465244269, createdTime=Wed Apr 07 20:40:24 CST 2021, time=2021-04-07, status=1, ipAttribution=)]
    2021-04-07 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1256826, encodeId=b4e21256826a5, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Apr 09 11:03:31 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283836, encodeId=57bd1283836a6, content=<a href='/topic/show?id=082842228d3' target=_blank style='color:#2F92EE;'>#塞来昔布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42228, encryptionId=082842228d3, topicName=塞来昔布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Fri Apr 09 11:03:31 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455469, encodeId=8d521455469ef, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Fri Apr 09 11:03:31 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955329, encodeId=367995532910, content=明白了没有提高作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc12612169, createdName=yqbs11, createdTime=Thu Apr 08 22:57:44 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955118, encodeId=78bf955118d9, content=无提高作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210208/c3dc2580e0ac4c8191eae47c717138a5/1e85aea19cb54b3da3746e58584795cf.jpg, createdBy=a3975411105, createdName=Half, createdTime=Thu Apr 08 08:31:23 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036564, encodeId=aa7d1036564d2, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Apr 07 23:03:31 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955087, encodeId=e44395508e1b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210406/5c10cde452f54a839edb1f37a9ed13a6/44169360eb0a44cba38dd6d204ba7d2f.jpg, createdBy=11d95477523, createdName=回首向来萧瑟处, createdTime=Wed Apr 07 23:01:34 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955042, encodeId=f26f95504243, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210315/24d1758726dd4fabb0a861d94a0f4a61/12d8ebfef4a14a3ebeab5b4335ebb394.jpg, createdBy=b6ef5464690, createdName=谭术, createdTime=Wed Apr 07 21:04:52 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955037, encodeId=564495503efd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e815440258, createdName=ms6000001465244269, createdTime=Wed Apr 07 20:40:24 CST 2021, time=2021-04-07, status=1, ipAttribution=)]
    2021-04-07 回首向来萧瑟处

    学习了

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1256826, encodeId=b4e21256826a5, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Apr 09 11:03:31 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283836, encodeId=57bd1283836a6, content=<a href='/topic/show?id=082842228d3' target=_blank style='color:#2F92EE;'>#塞来昔布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42228, encryptionId=082842228d3, topicName=塞来昔布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Fri Apr 09 11:03:31 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455469, encodeId=8d521455469ef, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Fri Apr 09 11:03:31 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955329, encodeId=367995532910, content=明白了没有提高作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc12612169, createdName=yqbs11, createdTime=Thu Apr 08 22:57:44 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955118, encodeId=78bf955118d9, content=无提高作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210208/c3dc2580e0ac4c8191eae47c717138a5/1e85aea19cb54b3da3746e58584795cf.jpg, createdBy=a3975411105, createdName=Half, createdTime=Thu Apr 08 08:31:23 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036564, encodeId=aa7d1036564d2, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Apr 07 23:03:31 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955087, encodeId=e44395508e1b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210406/5c10cde452f54a839edb1f37a9ed13a6/44169360eb0a44cba38dd6d204ba7d2f.jpg, createdBy=11d95477523, createdName=回首向来萧瑟处, createdTime=Wed Apr 07 23:01:34 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955042, encodeId=f26f95504243, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210315/24d1758726dd4fabb0a861d94a0f4a61/12d8ebfef4a14a3ebeab5b4335ebb394.jpg, createdBy=b6ef5464690, createdName=谭术, createdTime=Wed Apr 07 21:04:52 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955037, encodeId=564495503efd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e815440258, createdName=ms6000001465244269, createdTime=Wed Apr 07 20:40:24 CST 2021, time=2021-04-07, status=1, ipAttribution=)]
    2021-04-07 谭术

    学习了

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1256826, encodeId=b4e21256826a5, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Apr 09 11:03:31 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283836, encodeId=57bd1283836a6, content=<a href='/topic/show?id=082842228d3' target=_blank style='color:#2F92EE;'>#塞来昔布#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42228, encryptionId=082842228d3, topicName=塞来昔布)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Fri Apr 09 11:03:31 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455469, encodeId=8d521455469ef, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Fri Apr 09 11:03:31 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955329, encodeId=367995532910, content=明白了没有提高作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc12612169, createdName=yqbs11, createdTime=Thu Apr 08 22:57:44 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955118, encodeId=78bf955118d9, content=无提高作用, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210208/c3dc2580e0ac4c8191eae47c717138a5/1e85aea19cb54b3da3746e58584795cf.jpg, createdBy=a3975411105, createdName=Half, createdTime=Thu Apr 08 08:31:23 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036564, encodeId=aa7d1036564d2, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Apr 07 23:03:31 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955087, encodeId=e44395508e1b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210406/5c10cde452f54a839edb1f37a9ed13a6/44169360eb0a44cba38dd6d204ba7d2f.jpg, createdBy=11d95477523, createdName=回首向来萧瑟处, createdTime=Wed Apr 07 23:01:34 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955042, encodeId=f26f95504243, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210315/24d1758726dd4fabb0a861d94a0f4a61/12d8ebfef4a14a3ebeab5b4335ebb394.jpg, createdBy=b6ef5464690, createdName=谭术, createdTime=Wed Apr 07 21:04:52 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955037, encodeId=564495503efd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e815440258, createdName=ms6000001465244269, createdTime=Wed Apr 07 20:40:24 CST 2021, time=2021-04-07, status=1, ipAttribution=)]
    2021-04-07 ms6000001465244269

    学习了

    0

相关资讯

Gastroenterology:重复粪便免疫化学测试与乙状结肠镜检查对结直肠癌筛查的准确性差异

结直肠癌(CRC)是一种相对高发的肿瘤疾病,成为了全球健康成本的主要负担,2018年全球估计有180万新发病例,因此,尽早进行结肠癌筛查可以有效降低肿瘤的发生。

Gastroenterology:一种新型益生菌——嗜热链球菌可以抑制结直肠肿瘤发生

大肠癌(CRC)是全球第三大常见癌症,也是第四大癌症相关死亡的主要原因。

DCR:直肠癌患者行结肠切除后切缘阳性及术后并发症的高发的风险分析

大多数直肠癌都局限在直肠系膜筋膜内,尤其是在引入直肠癌早期筛查之后,全直肠系膜切除术(TME)是具有优异长期效果的标准外科手术切除术。

AJG:人体中性激素的异常与胃癌和结肠直肠癌有关,而与食管腺癌无关

无论是食道癌,胃癌还是结肠直肠癌都有一个无法解释的现象那就是男性占大多数。特别是是食管癌中,男性的发病率比女性高8倍。

Gastroenterology :45岁后要定期做肠镜

45-49岁时接受结肠镜检查与随后的大肠癌发病率显著降低有很强的相关性。

Br J Cancer:结肠癌患者术前全身炎症反应(SIR)测定的预后价值

每年全球大约诊断出120万例新的结肠癌病例以及约有500,000例的死亡病例。